Christopher M. Mela

563 total citations
16 papers, 374 citations indexed

About

Christopher M. Mela is a scholar working on Rheumatology, Immunology and Virology. According to data from OpenAlex, Christopher M. Mela has authored 16 papers receiving a total of 374 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Rheumatology, 7 papers in Immunology and 5 papers in Virology. Recurrent topics in Christopher M. Mela's work include Immune Cell Function and Interaction (6 papers), Rheumatoid Arthritis Research and Therapies (6 papers) and HIV Research and Treatment (5 papers). Christopher M. Mela is often cited by papers focused on Immune Cell Function and Interaction (6 papers), Rheumatoid Arthritis Research and Therapies (6 papers) and HIV Research and Treatment (5 papers). Christopher M. Mela collaborates with scholars based in United Kingdom, United States and Mexico. Christopher M. Mela's co-authors include Martin R. Goodier, Alan Steel, Brian Gazzard, Roy Fleischmann, James O. Lindsay, Joel M. Kremer, Rubén Burgos‐Vargas, Marek Brzosko, Frances Gotch and Emma Vernon and has published in prestigious journals such as Journal of Virology, Journal of the American Society of Nephrology and Annals of the Rheumatic Diseases.

In The Last Decade

Christopher M. Mela

16 papers receiving 365 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christopher M. Mela United Kingdom 9 229 129 69 69 64 16 374
H. Rodrigues Brazil 12 122 0.5× 66 0.5× 24 0.3× 19 0.3× 45 0.7× 37 408
H. Deicher Germany 10 111 0.5× 66 0.5× 18 0.3× 87 1.3× 40 0.6× 26 336
Catherine Van Kerckhove United States 10 229 1.0× 90 0.7× 9 0.1× 136 2.0× 37 0.6× 15 360
Jusnara Begum United Kingdom 11 189 0.8× 26 0.2× 20 0.3× 42 0.6× 143 2.2× 14 351
Hanns-Martin Lorenz Germany 10 96 0.4× 95 0.7× 10 0.1× 17 0.2× 52 0.8× 12 478
Rosario Nadorra United States 9 49 0.2× 148 1.1× 32 0.5× 63 0.9× 24 0.4× 10 331
Satoshi Shiokawa Japan 10 227 1.0× 35 0.3× 11 0.2× 65 0.9× 32 0.5× 24 375
P.M. van den Berg-Loonen Netherlands 11 116 0.5× 26 0.2× 12 0.2× 73 1.1× 58 0.9× 21 393
Rosamaria Rosso Italy 11 122 0.5× 16 0.1× 58 0.8× 150 2.2× 72 1.1× 29 400
M Pulik France 9 78 0.3× 47 0.4× 14 0.2× 61 0.9× 49 0.8× 37 276

Countries citing papers authored by Christopher M. Mela

Since Specialization
Citations

This map shows the geographic impact of Christopher M. Mela's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher M. Mela with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher M. Mela more than expected).

Fields of papers citing papers by Christopher M. Mela

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher M. Mela. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher M. Mela. The network helps show where Christopher M. Mela may publish in the future.

Co-authorship network of co-authors of Christopher M. Mela

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher M. Mela. A scholar is included among the top collaborators of Christopher M. Mela based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher M. Mela. Christopher M. Mela is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Parikh, Samir V., Cristina Arriens, Lucy S. Hodge, Christopher M. Mela, & Henry Leher. (2022). Voclosporin for Lupus Nephritis: Assessment of Long-Term Safety and Efficacy Including Renal Outcome Over 3 Years of Treatment in the Phase 3 AURORA 1 and AURORA 2 Studies. Journal of the American Society of Nephrology. 33(11S). 184–184. 1 indexed citations
2.
Saxena, Amit, et al.. (2021). POS0681 VOCLOSPORIN FOR LUPUS NEPHRITIS: INTERIM ANALYSIS OF THE AURORA 2 EXTENSION STUDY. Annals of the Rheumatic Diseases. 80. 585–586. 1 indexed citations
3.
Saxena, Amit, et al.. (2021). 514 Voclosporin for lupus nephritis: interim analysis of the AURORA 2 extension study. Abstracts. A20–A21. 1 indexed citations
4.
Fettner, Scott, et al.. (2019). Evidence of bioequivalence and positive patient user handling of a tocilizumab autoinjector. Expert Opinion on Drug Delivery. 16(5). 551–561. 12 indexed citations
5.
Boers, Maarten, Daniel Aletaha, Christopher M. Mela, Daniel G. Baker, & Josef S Smolen. (2016). Glucocorticoid Effect on Radiographic Progression in Placebo Arms of Rheumatoid Arthritis Biologics Trials. The Journal of Rheumatology. 43(6). 1024–1026. 1 indexed citations
6.
Kremer, Joel M., Ricardo Blanco, Marek Brzosko, et al.. (2016). Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trial.. PubMed. 34(4). 625–33. 22 indexed citations
7.
Fleischmann, Roy, Marek Brzosko, Rubén Burgos‐Vargas, et al.. (2013). Tocilizumab Inhibits Structural Joint Damage and Improves Physical Function in Patients with Rheumatoid Arthritis and Inadequate Responses to Methotrexate: LITHE Study 2-year Results. The Journal of Rheumatology. 40(2). 113–126. 84 indexed citations
8.
Kremer, Joel, Marek Brzosko, Rubén Burgos‐Vargas, et al.. (2013). SAT0103 Lithe: Tocilizumab (TCZ) Inhibits Radiographic Progression and Improves Physical Function in Patients (PTS) With Rheumatoid Arthritis (RA) at 5 Years With Maintenance of Clinical Efficacy Over Time. Annals of the Rheumatic Diseases. 72. A614–A615. 4 indexed citations
9.
Gregson, John, Leticia Kuri-Cervantes, Christopher M. Mela, et al.. (2012). Short Communication: NKG2C + NK Cells Contribute to Increases in CD16 + CD56 − Cells in HIV Type 1 + Individuals with High Plasma Viral Load. AIDS Research and Human Retroviruses. 29(1). 84–88. 15 indexed citations
10.
Rigby, William F. C., Gianfranco Ferraccioli, Maria Greenwald, et al.. (2010). Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. Arthritis Care & Research. 63(5). 711–720. 43 indexed citations
11.
Steel, Alan, Christopher M. Mela, James O. Lindsay, B Gazzard, & Martin R. Goodier. (2010). Increased proportion of CD16+ NK cells in the colonic lamina propria of inflammatory bowel disease patients, but not after azathioprine treatment. Alimentary Pharmacology & Therapeutics. 33(1). 115–126. 59 indexed citations
12.
Mela, Christopher M., Alan Steel, James O. Lindsay, et al.. (2007). Depletion of natural killer cells in the colonic lamina propria of viraemic HIV-1-infected individuals. AIDS. 21(16). 2177–2182. 22 indexed citations
13.
Goodier, Martin R., Christopher M. Mela, Alan Steel, et al.. (2006). NKG2C + NK Cells Are Enriched in AIDS Patients with Advanced-Stage Kaposi's Sarcoma. Journal of Virology. 81(1). 430–433. 23 indexed citations
14.
Burton, Catherine, Christopher M. Mela, Guglielmo Rosignoli, et al.. (2006). Immune Modulation and Reconstitution of HIV-1-Specific Responses: Novel Approaches and Strategies. Current Medicinal Chemistry. 13(26). 3203–3211. 3 indexed citations
15.
Mela, Christopher M., Catherine Burton, Nesrina Imami, et al.. (2005). Switch from inhibitory to activating NKG2 receptor expression in HIV-1 infection: lack of reversion with highly active antiretroviral therapy. AIDS. 19(16). 1761–1769. 75 indexed citations
16.
Imami, Nesrina, Gareth Hardy, António Pires, et al.. (2002). Immune reconstitution in HIV-1-infected patients.. PubMed. 3(8). 1138–45. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by H. Rodrigues Breakdown of academic impact, for papers by H. Deicher Breakdown of academic impact, for papers by Catherine Van Kerckhove Breakdown of academic impact, for papers by Jusnara Begum Breakdown of academic impact, for papers by Hanns-Martin Lorenz Breakdown of academic impact, for papers by Rosario Nadorra Breakdown of academic impact, for papers by Satoshi Shiokawa Breakdown of academic impact, for papers by P.M. van den Berg-Loonen Breakdown of academic impact, for papers by Rosamaria Rosso Breakdown of academic impact, for papers by M Pulik
Rankless by CCL
2026